The global de-identified health data market was valued at USD 8.09 billion in 2024 and is projected to reach USD 13.59 billion by 2030, expanding at a CAGR of 9.07% from 2025 to 2030. Market growth is fueled by the increasing integration of data analytics in healthcare, enabling large-scale studies and predictive modeling while safeguarding patient privacy.
De-identified health data plays a critical role in clinical research, allowing researchers to analyze extensive datasets without exposing personal identifiers. This type of data helps uncover population-level trends, assess treatment effectiveness, support public health initiatives, and improve evidence-based decision-making. By leveraging de-identified datasets, researchers can generate more accurate insights and drive advancements in medical knowledge, innovation, and care delivery—without compromising confidentiality.
Key Market Trends & Insights
- North America dominated the market with over 31.53% revenue share in 2024.
- The U.S. market is propelled by a robust healthcare system and strong investments in health information technology.
- By type of data, the clinical data segment accounted for the largest share at approximately 17.00% in 2024.
- By application, clinical research and trials led the market in 2024.
- By end use, healthcare providers held the largest revenue share in 2024.
Download a free sample PDF of the De-identified Health Data Market Intelligence Study by Grand View Research.
Market Size & Forecast
- 2024 Market Size: USD 8.09 Billion
- 2030 Projected Market Size: USD 13.59 Billion
- CAGR (2025–2030): 9.07%
- Largest Regional Market (2024): North America
Competitive Landscape
Industry players are increasingly engaging in collaborations, partnerships, and mergers & acquisitions to strengthen their market position and expand capabilities.
Prominent Companies
- IQVIA
- Oracle (Cerner Corporation)
- Merative (Truven Health Analytics)
- Optum, Inc. (UnitedHealth Group)
- ICON plc
- Veradigm LLC (formerly Allscripts)
- IBM
- Flatiron Health (F. Hoffmann-La Roche Ltd)
- Premier, Inc.
- Shaip
Recent Developments
- September 2024 – ICON & Intel Collaboration:
ICON partnered with Intel to integrate de-identified clinical data with Intel’s AI technologies. The initiative enhances patient recruitment, streamlines trial operations, and advances precision medicine by improving drug development efficiency and outcomes. - February 2024 – Veradigm Insights Report:
Veradigm published its first Veradigm Insights Report: Cardiovascular Conditions in 2024, featuring analysis of de-identified real-world data from 53 million U.S. cardiovascular patients. The report evaluates CVD prevalence across states and demographics, including age, ethnicity, and sex.
Explore Horizon Databook – the world’s most comprehensive market intelligence platform by Grand View Research.
Conclusion
The de-identified health data market is poised for strong expansion through 2030, supported by growing adoption of real-world evidence, rising digitalization in healthcare, and increasing regulatory focus on data privacy. As organizations continue to invest in analytics, AI, and large-scale research initiatives, de-identified health data will remain essential for advancing medical innovation while maintaining patient confidentiality.
No comments:
Post a Comment